Dr Cao Ling is a Consultant haematologist at Tan Tock Seng Hospital (TTSH), Singapore. Her core practice covers diagnostic and therapeutic haematology with a focus on plasma cell dyscrasias and lymphoid malignancies. She is actively involved in clinical research and service development in myeloma and lymphoma management.

Her clinical services include comprehensive management of multiple myeloma, lymphoma, and other haematologic malignancies, encompassing chemotherapy, targeted and immunotherapy delivery, and coordination of autologous transplantation care. She has a special interest in treatment resistance mechanisms and the application of novel targeted agents such as Bruton's tyrosine kinase inhibitors in lymphoid cancers.

Dr Cao received her basic medical training at Zhejiang University (China), followed by a Master of Medicine (Internal Medicine) from the Yong Loo Lin School of Medicine, National University of Singapore, and Membership of the Royal Colleges of Physicians (UK) in 2015. She completed SingHealth Internal Medicine and Haematology Senior Residency training, obtaining specialist accreditation in 2020.

She is a member of Singapore Myeloma Study Group and currently serves as co-Investigator for multiple haematological malignancies and CAR-T therapy in autoimmune diseases trials. Her academic work includes publications in American Journal of Medicine, American Journal of Hematology, and Leukaemia & Lymphoma journals.

Dr Cao believes in a patient-centred and evidence-based approach—combining compassion, communication, and research-driven care to improve each patient's treatment journey and quality of life.